Jeff Jonas, portfolio manager at Gabelli Funds, is cautious on the deal, mostly due to antitrust concerns. ‘JNJ has a late-stage Depression drug and has always been a leader in Schizophrenia
Jeff Jonas, portfolio manager at Gabelli Funds, is cautious on the deal, mostly due to antitrust concerns. ‘JNJ has a late-stage Depression drug and has always been a leader in Schizophrenia
